CliffBio
biologic

Datroway

datopotamab deruxtecan-dlnk

Loss of exclusivityJanuary 2037projected — 12-year biologic exclusivity estimate
CompanyDaiichi Sankyo →See this company's full patent-cliff portfolio

Drug detail

Brand nameDatroway
Active ingredientdatopotamab deruxtecan-dlnk
Strength100MG
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalJanuary 2025
Marketing statusRx

More from Daiichi Sankyo

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Datroway patent cliff — loss of exclusivity January 2037 | CliffBio